Headquartered in Wayne, PA·Fiscal year ends December·NASDAQ: AVTX·avalotx.com
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that target the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases.
Its lead candidate is abdakibart (AVTX-009), a humanized IgG4 monoclonal antibody that binds IL-1β with high affinity and neutralizes it. Following positive Phase 2 LOTUS trial results in hidradenitis suppurativa (HS), abdakibart is being prepared for a registrational Phase 3 program. HS is a chronic inflammatory skin condition estimated to affect 1-4% of the global population. Phase 3 initiation is planned for the first half of 2027, after FDA feedback expected by year-end 2026.
Avalo is also developing AVTX-010, a next-generation, Fc-engineered, long-acting anti-IL-1β antibody designed to extend half-life while preserving abdakibart's pharmacology. An IND submission is targeted for the first half of 2027 for potential use in HS and other inflammatory diseases.
The company is pursuing additional IL-1β-driven indications. It held [USD:462800000] in cash, cash equivalents and investments as of September 30, 2026, which it expects to fund operations into 2029. Updated
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline…
Avalo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that target the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases.
What is the AVTX stock price target?
The Wall Street consensus 12-month price target for AVTX is $34.80.